SCNI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SCNI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Scinai Immunotherapeutics's annualized ROCE % for the quarter that ended in Sep. 2023 was -47.97%.
The historical data trend for Scinai Immunotherapeutics's ROCE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scinai Immunotherapeutics Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
ROCE % | Get a 7-Day Free Trial | -89.86 | -108.32 | -8.07 | -79.49 | -40.72 |
Scinai Immunotherapeutics Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
ROCE % | Get a 7-Day Free Trial | -46.27 | -54.67 | -56.09 | -53.61 | -47.97 |
Scinai Immunotherapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:
ROCE % | = | EBIT | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(A: Dec. 2022 ) | (A: Dec. 2021 ) | (A: Dec. 2022 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(A: Dec. 2022 ) | (A: Dec. 2021 ) | (A: Dec. 2022 ) | |||||
= | -11.061 | / | ( ( (32.036 - 2.444) | + | (27.067 - 2.338) ) | / 2 ) | |
= | -11.061 | / | ( (29.592 | + | 24.729) | / 2 ) | |
= | -11.061 | / | 27.1605 | ||||
= | -40.72 % |
Scinai Immunotherapeutics's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:
ROCE % | = | EBIT (1) | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(Q: Sep. 2023 ) | (Q: Jun. 2023 ) | (Q: Sep. 2023 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(Q: Sep. 2023 ) | (Q: Jun. 2023 ) | (Q: Sep. 2023 ) | |||||
= | -8.408 | / | ( ( (19.897 - 1.888) | + | (18.582 - 1.538) ) | / 2 ) | |
= | -8.408 | / | ( ( 18.009 | + | 17.044 ) | / 2 ) | |
= | -8.408 | / | 17.5265 | ||||
= | -47.97 % |
(1) Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scinai Immunotherapeutics (NAS:SCNI) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Thank you for viewing the detailed overview of Scinai Immunotherapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Samuel J Moed | director | BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543 |
Mark Germain | director, other: Chairman | WELLSFORD REAL PROPERTIES INC, 535 MADISON AVENUE, NEW YORK NY 10022 |
Uri Ben-or | officer: Chief Financial Officer | C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002 |
Yael Margolin | director | 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268 |
Adi Raviv | director | STRAUS CAPITAL GROUP, 411 HACKENSACK AVENUE, 7TH FLOOR, HACKENSACK NJ 07601 |
Morris C Laster | director | 11 REUVEN SHARI ST., JERUSALEM L3 9724611 |
Tamar Ben-yedidia | officer: Chief Scientist | 6 HAZIT ST., MAZKERET BATIA L3 7685421 |
Avner Rotman | director | 21 EISENBERG ST., REHOVOT L3 7628905 |
Amir Reichman | director, officer: Chief Executive Officer | 269 NAHAL FARAN ST., TAL SHAHAR L3 7680500 |
Elad Mark | officer: Chief Operating Officer | 27 HAILANOT, HERZLIYA L3 4631214 |
George Lowell | director | 33 DERECH BEIT LECHEM ST., JERUSALEM L3 9355317 |
Jay Green | director | 354 CONCESSION 10 E, FREELTON, ON Z4 L8B 1H6 |
From GuruFocus
By PRNewswire • 01-04-2024
By ACCESSWIRE ACCESSWIRE • 05-16-2023
By sperokesalga sperokesalga • 06-05-2023
By PRNewswire • 11-29-2023
By PRNewswire • 01-04-2024
By PRNewswire • 12-27-2023
By Marketwired • 10-30-2023
By Stock market mentor Stock market mentor • 02-02-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.